Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 18/20 | 0.55 |
| ▸ | RBP4 | P02753 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CDK16 | Q00536 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.46 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.46 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL5562107 | 0.96 | GSK3B (0.52) | GSK3BRBP4CDK2CDK16DYRK1A | |
| SCHEMBL5044513 | 0.92 | GSK3B (0.52) | GSK3BRBP4CDK2CDK16DYRK1A | |
| SCHEMBL1176725 | 0.92 | GSK3B (0.46) | GSK3BRBP4CDK2CDK16DYRK1A | |
| SCHEMBL1175931 | 0.92 | GSK3B (0.52) | GSK3BRBP4CDK2CDK16DYRK1A | |
| Hydrochloric Acid SCHEMBL1175804 | 0.91 | GSK3B (0.52) | GSK3BRBP4CDK2CDK16DYRK1A | |
| Formic Acid SCHEMBL5561747 | 0.88 | GSK3B (0.43) | GSK3BRBP4CDK2CDK16DYRK1A | |
| Formic Acid SCHEMBL5556319 | 0.88 | GSK3B (0.49) | GSK3BRBP4CDK2CDK16DYRK1A | |
| SCHEMBL1176262 | 0.86 | DYRK1A (0.42) | GSK3BRBP4DYRK1A | |
| SCHEMBL5048444 | 0.84 | PRKAG1 (0.58) | GSK3BRBP4DYRK1APRKAG1PRKAA1 | |
| SCHEMBL1176665 | 0.84 | PRKAG1 (0.58) | GSK3BRBP4DYRK1APRKAG1PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4824578-B2 | — | — | 2011-11-30 | — | — | JP | claimed |
| US-7396833-B2 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-07-08 | — | — | US | claimed |
| EP-1697378-B1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARM CORP (US) | 2007-11-21 | — | — | EP | claimed |
| EP-1697378-A2 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF | Memory Pharmaceuticals Corporation (US) | 2006-09-06 | — | — | EP | claimed |
| US-20050176754-A1 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2005-08-11 | — | — | US | claimed |
| WO-2005063767-A2 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-07-14 | — | — | WO | claimed |
| US-8158629-B2 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158629-B2 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158629-B2 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-20110312989-A1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312989-A1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312989-A1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE (US) | 2011-12-22 | — | — | US | disclosed |
| US-7964600-B2 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2011-06-21 | — | — | US | disclosed |
| US-7396833-B2 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396833-B2 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396833-B2 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-07-08 | — | — | US | disclosed |
| EP-1697378-B1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARM CORP (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1697378-A2 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF | Memory Pharmaceuticals Corporation (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050176754-A1 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2005-08-11 | — | — | US | disclosed |
| WO-2005063767-A2 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312989-A1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA1 | GSK3B 608/4885RBP4 4283/4885CDK2 1206/4885 |
| US-20050176754-A1 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA1 | GSK3B 608/4885RBP4 4283/4885CDK2 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.